{
  "hash": "232705a6e40d38bcbf44d098e2e424f0",
  "result": {
    "engine": "knitr",
    "markdown": "---\ntitle: \"Glioma (GBM, IDH-wildtype) — Caso MTB\"\n---\n\n::: {.cell}\n\n```{.r .cell-code}\nlibrary(readr); library(dplyr); library(gt)\nsom <- read_csv(\"data/gbm_variants_somatic.csv\")\ngerm <- read_csv(\"data/gbm_variants_germline.csv\")\n```\n:::\n\n\n\n\n\n### Sintesi clinica\n\n\\`\\`\\`{{=include}} templates/clinical_gbm.md\n\n### Varianti somatiche\n\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code}\ngt(som) |> tab_caption(\"GBM-01 — Somatic variants (tiering AMP/ASCO/CAP, ESCAT)\")\n```\n\n::: {.cell-output-display}\n\n```{=html}\n<div id=\"pyhzqatmpu\" style=\"padding-left:0px;padding-right:0px;padding-top:10px;padding-bottom:10px;overflow-x:auto;overflow-y:auto;width:auto;height:auto;\">\n<style>#pyhzqatmpu table {\n  font-family: system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji';\n  -webkit-font-smoothing: antialiased;\n  -moz-osx-font-smoothing: grayscale;\n}\n\n#pyhzqatmpu thead, #pyhzqatmpu tbody, #pyhzqatmpu tfoot, #pyhzqatmpu tr, #pyhzqatmpu td, #pyhzqatmpu th {\n  border-style: none;\n}\n\n#pyhzqatmpu p {\n  margin: 0;\n  padding: 0;\n}\n\n#pyhzqatmpu .gt_table {\n  display: table;\n  border-collapse: collapse;\n  line-height: normal;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #FFFFFF;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#pyhzqatmpu .gt_caption {\n  padding-top: 4px;\n  padding-bottom: 4px;\n}\n\n#pyhzqatmpu .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-color: #FFFFFF;\n  border-bottom-width: 0;\n}\n\n#pyhzqatmpu .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 3px;\n  padding-bottom: 5px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-color: #FFFFFF;\n  border-top-width: 0;\n}\n\n#pyhzqatmpu .gt_heading {\n  background-color: #FFFFFF;\n  text-align: center;\n  border-bottom-color: #FFFFFF;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#pyhzqatmpu .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#pyhzqatmpu .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#pyhzqatmpu .gt_col_heading {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#pyhzqatmpu .gt_column_spanner_outer {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#pyhzqatmpu .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#pyhzqatmpu .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#pyhzqatmpu .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 5px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#pyhzqatmpu .gt_spanner_row {\n  border-bottom-style: hidden;\n}\n\n#pyhzqatmpu .gt_group_heading {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  text-align: left;\n}\n\n#pyhzqatmpu .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#pyhzqatmpu .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#pyhzqatmpu .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#pyhzqatmpu .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#pyhzqatmpu .gt_stub {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#pyhzqatmpu .gt_stub_row_group {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 5px;\n  padding-right: 5px;\n  vertical-align: top;\n}\n\n#pyhzqatmpu .gt_row_group_first td {\n  border-top-width: 2px;\n}\n\n#pyhzqatmpu .gt_row_group_first th {\n  border-top-width: 2px;\n}\n\n#pyhzqatmpu .gt_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#pyhzqatmpu .gt_first_summary_row {\n  border-top-style: solid;\n  border-top-color: #D3D3D3;\n}\n\n#pyhzqatmpu .gt_first_summary_row.thick {\n  border-top-width: 2px;\n}\n\n#pyhzqatmpu .gt_last_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#pyhzqatmpu .gt_grand_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#pyhzqatmpu .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#pyhzqatmpu .gt_last_grand_summary_row_top {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-style: double;\n  border-bottom-width: 6px;\n  border-bottom-color: #D3D3D3;\n}\n\n#pyhzqatmpu .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#pyhzqatmpu .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#pyhzqatmpu .gt_footnotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#pyhzqatmpu .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#pyhzqatmpu .gt_sourcenotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#pyhzqatmpu .gt_sourcenote {\n  font-size: 90%;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#pyhzqatmpu .gt_left {\n  text-align: left;\n}\n\n#pyhzqatmpu .gt_center {\n  text-align: center;\n}\n\n#pyhzqatmpu .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#pyhzqatmpu .gt_font_normal {\n  font-weight: normal;\n}\n\n#pyhzqatmpu .gt_font_bold {\n  font-weight: bold;\n}\n\n#pyhzqatmpu .gt_font_italic {\n  font-style: italic;\n}\n\n#pyhzqatmpu .gt_super {\n  font-size: 65%;\n}\n\n#pyhzqatmpu .gt_footnote_marks {\n  font-size: 75%;\n  vertical-align: 0.4em;\n  position: initial;\n}\n\n#pyhzqatmpu .gt_asterisk {\n  font-size: 100%;\n  vertical-align: 0;\n}\n\n#pyhzqatmpu .gt_indent_1 {\n  text-indent: 5px;\n}\n\n#pyhzqatmpu .gt_indent_2 {\n  text-indent: 10px;\n}\n\n#pyhzqatmpu .gt_indent_3 {\n  text-indent: 15px;\n}\n\n#pyhzqatmpu .gt_indent_4 {\n  text-indent: 20px;\n}\n\n#pyhzqatmpu .gt_indent_5 {\n  text-indent: 25px;\n}\n\n#pyhzqatmpu .katex-display {\n  display: inline-flex !important;\n  margin-bottom: 0.75em !important;\n}\n\n#pyhzqatmpu div.Reactable > div.rt-table > div.rt-thead > div.rt-tr.rt-tr-group-header > div.rt-th-group:after {\n  height: 0px !important;\n}\n</style>\n<table class=\"gt_table\" data-quarto-disable-processing=\"false\" data-quarto-bootstrap=\"false\">\n  <caption>GBM-01 — Somatic variants (tiering AMP/ASCO/CAP, ESCAT)</caption>\n  <thead>\n    <tr class=\"gt_col_headings\">\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"gene\">gene</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"variant_cDNA\">variant_cDNA</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"variant_protein\">variant_protein</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"effect\">effect</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_right\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"vaf\">vaf</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_right\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"depth\">depth</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"copy_number\">copy_number</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"tier_amp_ascocap\">tier_amp_ascocap</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"escat\">escat</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"evidence_summary\">evidence_summary</th>\n    </tr>\n  </thead>\n  <tbody class=\"gt_table_body\">\n    <tr><td headers=\"gene\" class=\"gt_row gt_left\">EGFR</td>\n<td headers=\"variant_cDNA\" class=\"gt_row gt_left\">EGFRvIII (ex2-7 del)</td>\n<td headers=\"variant_protein\" class=\"gt_row gt_left\">p.Glu6_Ala273del</td>\n<td headers=\"effect\" class=\"gt_row gt_left\">Oncogenic activation</td>\n<td headers=\"vaf\" class=\"gt_row gt_right\">0.21</td>\n<td headers=\"depth\" class=\"gt_row gt_right\">450</td>\n<td headers=\"copy_number\" class=\"gt_row gt_left\">12</td>\n<td headers=\"tier_amp_ascocap\" class=\"gt_row gt_left\">Tier IA (biomarker)</td>\n<td headers=\"escat\" class=\"gt_row gt_left\">II-B</td>\n<td headers=\"evidence_summary\" class=\"gt_row gt_left\">Common GBM driver; investigational EGFRvIII-directed trials.</td></tr>\n    <tr><td headers=\"gene\" class=\"gt_row gt_left\">EGFR</td>\n<td headers=\"variant_cDNA\" class=\"gt_row gt_left\">amplicon</td>\n<td headers=\"variant_protein\" class=\"gt_row gt_left\">—</td>\n<td headers=\"effect\" class=\"gt_row gt_left\">Amplification</td>\n<td headers=\"vaf\" class=\"gt_row gt_right\">NA</td>\n<td headers=\"depth\" class=\"gt_row gt_right\">NA</td>\n<td headers=\"copy_number\" class=\"gt_row gt_left\">12</td>\n<td headers=\"tier_amp_ascocap\" class=\"gt_row gt_left\">Tier IA (biomarker)</td>\n<td headers=\"escat\" class=\"gt_row gt_left\">II-B</td>\n<td headers=\"evidence_summary\" class=\"gt_row gt_left\">High-level amplification; supports EGFR-targeted trial eligibility.</td></tr>\n    <tr><td headers=\"gene\" class=\"gt_row gt_left\">TERT</td>\n<td headers=\"variant_cDNA\" class=\"gt_row gt_left\">c.-124C&gt;T (C228T)</td>\n<td headers=\"variant_protein\" class=\"gt_row gt_left\">promoter</td>\n<td headers=\"effect\" class=\"gt_row gt_left\">Promoter activation</td>\n<td headers=\"vaf\" class=\"gt_row gt_right\">0.28</td>\n<td headers=\"depth\" class=\"gt_row gt_right\">600</td>\n<td headers=\"copy_number\" class=\"gt_row gt_left\">NA</td>\n<td headers=\"tier_amp_ascocap\" class=\"gt_row gt_left\">Tier IIIC</td>\n<td headers=\"escat\" class=\"gt_row gt_left\">Not ranked</td>\n<td headers=\"evidence_summary\" class=\"gt_row gt_left\">Prognostic; not directly actionable.</td></tr>\n    <tr><td headers=\"gene\" class=\"gt_row gt_left\">PTEN</td>\n<td headers=\"variant_cDNA\" class=\"gt_row gt_left\">c.389G&gt;A</td>\n<td headers=\"variant_protein\" class=\"gt_row gt_left\">p.R130Q</td>\n<td headers=\"effect\" class=\"gt_row gt_left\">Loss-of-function</td>\n<td headers=\"vaf\" class=\"gt_row gt_right\">0.34</td>\n<td headers=\"depth\" class=\"gt_row gt_right\">520</td>\n<td headers=\"copy_number\" class=\"gt_row gt_left\">loss</td>\n<td headers=\"tier_amp_ascocap\" class=\"gt_row gt_left\">Tier IIC</td>\n<td headers=\"escat\" class=\"gt_row gt_left\">III</td>\n<td headers=\"evidence_summary\" class=\"gt_row gt_left\">PI3K/AKT pathway activation; no approved targeted therapy in GBM.</td></tr>\n    <tr><td headers=\"gene\" class=\"gt_row gt_left\">CDKN2A/B</td>\n<td headers=\"variant_cDNA\" class=\"gt_row gt_left\">homozygous deletion</td>\n<td headers=\"variant_protein\" class=\"gt_row gt_left\">—</td>\n<td headers=\"effect\" class=\"gt_row gt_left\">Loss-of-function</td>\n<td headers=\"vaf\" class=\"gt_row gt_right\">NA</td>\n<td headers=\"depth\" class=\"gt_row gt_right\">NA</td>\n<td headers=\"copy_number\" class=\"gt_row gt_left\">0 copies</td>\n<td headers=\"tier_amp_ascocap\" class=\"gt_row gt_left\">Tier IIIC</td>\n<td headers=\"escat\" class=\"gt_row gt_left\">III</td>\n<td headers=\"evidence_summary\" class=\"gt_row gt_left\">Cell-cycle deregulation; may inform CDK pathway trial eligibility.</td></tr>\n    <tr><td headers=\"gene\" class=\"gt_row gt_left\">NF1</td>\n<td headers=\"variant_cDNA\" class=\"gt_row gt_left\">c.2033C&gt;A</td>\n<td headers=\"variant_protein\" class=\"gt_row gt_left\">p.S678*</td>\n<td headers=\"effect\" class=\"gt_row gt_left\">Truncating</td>\n<td headers=\"vaf\" class=\"gt_row gt_right\">0.12</td>\n<td headers=\"depth\" class=\"gt_row gt_right\">480</td>\n<td headers=\"copy_number\" class=\"gt_row gt_left\">NA</td>\n<td headers=\"tier_amp_ascocap\" class=\"gt_row gt_left\">Tier IIIC</td>\n<td headers=\"escat\" class=\"gt_row gt_left\">III</td>\n<td headers=\"evidence_summary\" class=\"gt_row gt_left\">RAS/MAPK activation; occasional MEK inhibitor trials.</td></tr>\n    <tr><td headers=\"gene\" class=\"gt_row gt_left\">PDGFRA</td>\n<td headers=\"variant_cDNA\" class=\"gt_row gt_left\">gain</td>\n<td headers=\"variant_protein\" class=\"gt_row gt_left\">—</td>\n<td headers=\"effect\" class=\"gt_row gt_left\">Copy number gain</td>\n<td headers=\"vaf\" class=\"gt_row gt_right\">NA</td>\n<td headers=\"depth\" class=\"gt_row gt_right\">NA</td>\n<td headers=\"copy_number\" class=\"gt_row gt_left\">4</td>\n<td headers=\"tier_amp_ascocap\" class=\"gt_row gt_left\">Tier IIIC</td>\n<td headers=\"escat\" class=\"gt_row gt_left\">III</td>\n<td headers=\"evidence_summary\" class=\"gt_row gt_left\">May expand RTK pathway trial options.</td></tr>\n  </tbody>\n  \n  \n</table>\n</div>\n```\n\n:::\n:::\n\n\n\n\n\n### Germinale (ricerca)\n\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code}\ngt(germ) |> tab_caption(\"GBM-01 — Variant-like segnali germinali (non validati, da confermare)\")\n```\n\n::: {.cell-output-display}\n\n```{=html}\n<div id=\"anjjkqddqg\" style=\"padding-left:0px;padding-right:0px;padding-top:10px;padding-bottom:10px;overflow-x:auto;overflow-y:auto;width:auto;height:auto;\">\n<style>#anjjkqddqg table {\n  font-family: system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji';\n  -webkit-font-smoothing: antialiased;\n  -moz-osx-font-smoothing: grayscale;\n}\n\n#anjjkqddqg thead, #anjjkqddqg tbody, #anjjkqddqg tfoot, #anjjkqddqg tr, #anjjkqddqg td, #anjjkqddqg th {\n  border-style: none;\n}\n\n#anjjkqddqg p {\n  margin: 0;\n  padding: 0;\n}\n\n#anjjkqddqg .gt_table {\n  display: table;\n  border-collapse: collapse;\n  line-height: normal;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #FFFFFF;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#anjjkqddqg .gt_caption {\n  padding-top: 4px;\n  padding-bottom: 4px;\n}\n\n#anjjkqddqg .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-color: #FFFFFF;\n  border-bottom-width: 0;\n}\n\n#anjjkqddqg .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 3px;\n  padding-bottom: 5px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-color: #FFFFFF;\n  border-top-width: 0;\n}\n\n#anjjkqddqg .gt_heading {\n  background-color: #FFFFFF;\n  text-align: center;\n  border-bottom-color: #FFFFFF;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#anjjkqddqg .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#anjjkqddqg .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#anjjkqddqg .gt_col_heading {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#anjjkqddqg .gt_column_spanner_outer {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#anjjkqddqg .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#anjjkqddqg .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#anjjkqddqg .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 5px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#anjjkqddqg .gt_spanner_row {\n  border-bottom-style: hidden;\n}\n\n#anjjkqddqg .gt_group_heading {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  text-align: left;\n}\n\n#anjjkqddqg .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#anjjkqddqg .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#anjjkqddqg .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#anjjkqddqg .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#anjjkqddqg .gt_stub {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#anjjkqddqg .gt_stub_row_group {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 5px;\n  padding-right: 5px;\n  vertical-align: top;\n}\n\n#anjjkqddqg .gt_row_group_first td {\n  border-top-width: 2px;\n}\n\n#anjjkqddqg .gt_row_group_first th {\n  border-top-width: 2px;\n}\n\n#anjjkqddqg .gt_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#anjjkqddqg .gt_first_summary_row {\n  border-top-style: solid;\n  border-top-color: #D3D3D3;\n}\n\n#anjjkqddqg .gt_first_summary_row.thick {\n  border-top-width: 2px;\n}\n\n#anjjkqddqg .gt_last_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#anjjkqddqg .gt_grand_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#anjjkqddqg .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#anjjkqddqg .gt_last_grand_summary_row_top {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-style: double;\n  border-bottom-width: 6px;\n  border-bottom-color: #D3D3D3;\n}\n\n#anjjkqddqg .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#anjjkqddqg .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#anjjkqddqg .gt_footnotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#anjjkqddqg .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#anjjkqddqg .gt_sourcenotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#anjjkqddqg .gt_sourcenote {\n  font-size: 90%;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#anjjkqddqg .gt_left {\n  text-align: left;\n}\n\n#anjjkqddqg .gt_center {\n  text-align: center;\n}\n\n#anjjkqddqg .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#anjjkqddqg .gt_font_normal {\n  font-weight: normal;\n}\n\n#anjjkqddqg .gt_font_bold {\n  font-weight: bold;\n}\n\n#anjjkqddqg .gt_font_italic {\n  font-style: italic;\n}\n\n#anjjkqddqg .gt_super {\n  font-size: 65%;\n}\n\n#anjjkqddqg .gt_footnote_marks {\n  font-size: 75%;\n  vertical-align: 0.4em;\n  position: initial;\n}\n\n#anjjkqddqg .gt_asterisk {\n  font-size: 100%;\n  vertical-align: 0;\n}\n\n#anjjkqddqg .gt_indent_1 {\n  text-indent: 5px;\n}\n\n#anjjkqddqg .gt_indent_2 {\n  text-indent: 10px;\n}\n\n#anjjkqddqg .gt_indent_3 {\n  text-indent: 15px;\n}\n\n#anjjkqddqg .gt_indent_4 {\n  text-indent: 20px;\n}\n\n#anjjkqddqg .gt_indent_5 {\n  text-indent: 25px;\n}\n\n#anjjkqddqg .katex-display {\n  display: inline-flex !important;\n  margin-bottom: 0.75em !important;\n}\n\n#anjjkqddqg div.Reactable > div.rt-table > div.rt-thead > div.rt-tr.rt-tr-group-header > div.rt-th-group:after {\n  height: 0px !important;\n}\n</style>\n<table class=\"gt_table\" data-quarto-disable-processing=\"false\" data-quarto-bootstrap=\"false\">\n  <caption>GBM-01 — Variant-like segnali germinali (non validati, da confermare)</caption>\n  <thead>\n    <tr class=\"gt_col_headings\">\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"gene\">gene</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"variant_cDNA\">variant_cDNA</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"variant_protein\">variant_protein</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"classification\">classification</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"reportable\">reportable</th>\n      <th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"note\">note</th>\n    </tr>\n  </thead>\n  <tbody class=\"gt_table_body\">\n    <tr><td headers=\"gene\" class=\"gt_row gt_left\">CHEK2</td>\n<td headers=\"variant_cDNA\" class=\"gt_row gt_left\">c.470T&gt;C</td>\n<td headers=\"variant_protein\" class=\"gt_row gt_left\">p.I157T</td>\n<td headers=\"classification\" class=\"gt_row gt_left\">VUS (research-only)</td>\n<td headers=\"reportable\" class=\"gt_row gt_left\">No</td>\n<td headers=\"note\" class=\"gt_row gt_left\">Detected on tumor-only; do not return clinically without matched normal.</td></tr>\n    <tr><td headers=\"gene\" class=\"gt_row gt_left\">DPYD</td>\n<td headers=\"variant_cDNA\" class=\"gt_row gt_left\">none</td>\n<td headers=\"variant_protein\" class=\"gt_row gt_left\">—</td>\n<td headers=\"classification\" class=\"gt_row gt_left\">No pathogenic variants</td>\n<td headers=\"reportable\" class=\"gt_row gt_left\">N/A</td>\n<td headers=\"note\" class=\"gt_row gt_left\">No fluoropyrimidine toxicity alleles observed.</td></tr>\n  </tbody>\n  \n  \n</table>\n</div>\n```\n\n:::\n:::\n\n\n\n\n\n::: callout-warning\n**Caveat tumor-only** — eventuali VUS non vanno riportati clinicamente; serve conferma su sangue/saliva in caso di sospetto germinale.\n:::\n\n### Discussione\n\n-   Alternative sistemiche.\n-   Trials\n\n| **Biomarker / Profilo** | **Farmaco / Strategia** | **Setting** | **Evidenza / Note 2025** |\n|----|----|----|----|\n| **EGFR amp + vIII** | Trial con inibitori EGFR/RTK | Recidiva / arruolamento trial | Opzione più promettente se disponibile trial; nessun standard consolidato. |\n| **MET (amp / exon14 / fusioni)** | Tepotinib, Capmatinib, Vebreltinib (solo in trial) | Recidiva con alterazione MET | Segnali clinici di beneficio (casi e basket trial). Priorità alta se presente. |\n| **ALK / ROS1 / NTRK fusioni** | Lorlatinib (ALK/ROS1), Entrectinib / Larotrectinib (ROS1/NTRK) | Recidiva; preferibilmente trial | Risposte documentate in case report. Uso sperimentale o off-label selezionato. |\n| **Nessun target disponibile** | **Regorafenib** | Recidiva non eleggibile a trial | Efficacia e tollerabilità confermate; opzione sistemica di riferimento. |\n| **Edema / sintomi severi** | **Bevacizumab** | Palliativo / in combinazione | Controllo sintomi e riduzione steroidi; non migliora OS. |\n| **IO (CPS\\~10, MSS, TMB-low)** | Anti-PD-1/PD-L1 (solo trial) | Sperimentale | Razionale debole in assenza di ipermutazione; non standard. |\n",
    "supporting": [
      "03_glioma_files"
    ],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {
      "include-in-header": [
        "<link href=\"site_libs/pagedtable-1.1/css/pagedtable.css\" rel=\"stylesheet\" />\n<script src=\"site_libs/pagedtable-1.1/js/pagedtable.js\"></script>\n"
      ]
    },
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}